NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Theriva Biologics, Inc. (TOVX) Stock Analysis

Theriva Biologics, Inc. (TOVX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

TOVX

$0.25

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TOVX with… →

TOVX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.26
Previous Close
$0.25
Day's Range
0.25–0.26
52-Week Range
0.16–0.86
Volume
431.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.15
Valuation
Market Cap
$11.61M
P/E Ratio
0.18
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
38.70
EPS (ttm)Profit attributable to each share over the last twelve months.
1.44
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$23.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.89M
1-Year Return
−35.90%
Dividend and dates
Avg Volume
6.03M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TOVX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+19.05%
2025−88.00%
2024−83.72%
2023−4.44%
2022−83.33%
2021−28.95%
2020−25.49%
2019−8.93%
2018−96.86%
2017−32.89%
2016 (partial year)−54.76%

As of September 4, 2026.

TOVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$23.74M—
2024$0.00−$25.65M—
2023$0.00−$18.35M—
2022$0.00−$19.69M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$24.05M−$23.74M—
2024$0.00—−$19.43M−$25.65M—
2023$0.00—−$21.43M−$18.35M—
2022$0.00—−$21.58M−$19.69M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TOVX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTOVXBiotechnology medianvs median
P/E0.1812.570.0x the median
P/S ratio38.7015.26154% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Theriva Biologics, Inc. (TOVX) at $11.61M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 15 employees.

TOVX last closed at $0.25 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.16 to $0.86. The latest close sits 56.25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $23.74M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 1.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

TOVX trades at a trailing price-to-earnings ratio of 0.18. That is 0 times the Biotechnology median of 12.57. Measured against sales, the shares trade at 38.7 times revenue. On price-to-sales that is 153.56% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.15. Daily returns over the trailing 10 years annualize to a volatility of 109.46%. The trailing one-year price return is −35.90%. Across 10 years the annualized return works out at −66.45%.

Growth & Income

No dividend is on file for TOVX.

So far in 2026 the price is +19.05%. The strongest complete calendar year on file is 2023 at −4.44%; the weakest is 2018 at −96.86%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Theriva Biologics, Inc. (TOVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Theriva Biologics, Inc. TOVX $11.61M 0.2
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Theriva Biologics, Inc. trades at a P/E of 0.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Theriva Biologics, Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Visit website →